Since p32 is a validated cancer target, we expect a small molecule inhibitor of p32 to be an effective therapeutic for glioma and other types of cancers overexpressing p32—e.g., melanoma, breast, colon, and prostate cancers [23]. This evidence concerns the gene C1QBP and Familial prostate cancer.